Skip to main content Deutsch

ReGenHeart

Sorry, this content is only available in German!

ReGenHeart

Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory anginaA phase II randomized, double-blinded, placebo-controlled study

http://cordis.europa.eu/project/rcn/207197_en.html

Call/Topic: H2020-SC1-PM-11-2016-2017 - Clinical Research on regenerative medicine
Project duration: 01/2017–06/2021
Total costs: € 5.934.088
Contribution MUW: € 621.668
The Medical University of Vienna acts as a project partner led by Prof. Dr. Mariann Gyöngyösi, Clinical Department of Internal Medicine II, Division of Cardiology.
Project coordinator is Prof. Dr. Seppo N., Pohjois-Savon sairaanhoitopiirin Kuntayhtyma, Finland
Consortium: 9 Partners

 

Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory anginaA phase II randomized, double-blinded, placebo-controlled study

Chronic angina pectoris is a debilitating chronic disease, a subgroup of these patients suffers from refractory angina which unfortunately can’t be controlled by medical therapy (angioplasty or surgery). Refractory angina is a substantial burden on the individual and healthcare system, in Europe there are 100,000 new cases per year, annual mortality of these patients is relatively low (<4%) thus refractory angina patients suffer multiple hospitalizations and low levels of health-related quality of life.

The ReGenHeart project is based on extensive preclinical work and a phase I safety, feasibility and dose-finding clinical study recently completed by the consortium. The project will conduct a multicentre, randomized, placebo-controlled, double-blinded Phase II clinical study to provide proof of concept and clinical validation for a new, percutaneous, cost-efficient therapy for refractory angina patients. Using our optimized catheter-mediated intramyocardial approach with AdenoVEGF-D, which has never been used in man before our phase I trial, we aim to induce regenerative changes supported by therapeutic angiogenesis in the affected area of a patient's heart and, in a single procedure, reduce the burden on the individual and their health service.

The proposed trial is ready to proceed, subject to final regulatory approval in the six European clinical centres. 180 CCS class 2-3 refractory angina patients will be recruited, which will allow us to assess the benefits of therapy to patients who still have potential to respond to the regenerative therapy. Patients will be randomized 2:1 to either the gene therapy or placebo arms.

Trial follow up, at 6 and 12 months, will assess how far they can walk in 6 minutes (primary endpoint) and also by their CCS angina score, quality of life, so-called MACE endpoints and several advanced PET and MRI imaging endpoints.

Arbeitsgruppe Univ. Prof. Univ.-Doz. Dr. Mariann Pavone-Gyöngyösi